Superintelligence CouncilСовет гения · sim.im

Gary Halbert · whole document (49)

zhlk promote website

You know what is so great about many of those smaller,
low-priced publicly-traded companies? Not only does a low-priced stock have
more "growing room," many of them remain unexamined by the big
institutional investors who are insurance companies, pension funds and mutual
funds. They can't afford to mess with those "little" stocks. First
of all, there are more mutual funds than stocks (I find that rather
amazing) and often, one day's trading in a given mutual fund is more than ten
times the entire value of a small or micro cap company. Many of those small
companies have spectacular "news" relatively no one knows about.
Like a company called Longport which has a portable skin scanner a doctor can
use to detect skin cancer in seconds... before
it is visible... and without a
biopsy.

By the way, I have not
invested in Longport because it is not traded on any of the three major
exchanges. But, if it was, I would invest in it... because... not only
do the stocks I invest in have to get through my price parameters, volume
parameters and all the other hurdles...

They Must Also Have

A Terrific And Mostly

Untold Story!

Plus, these have to be
stories... that... I have reason to believe the mainstream investment
publications are about to "discover."

OK, now that you know
all that, here are the stocks I've invested in this month:

STOCK
#1:

Company

Ticker

Exchange

Cortex Pharmaceuticals, Inc.

(An
Alzheimer's Breakthrough?)

CORX

NASDAQ

This is a neuroscience company focused on novel drug therapies for
neurological and psychiatric disorders. Recently, a patent application has
been filed entitled "Facilitation of AMPA Synoptic Transmission in Brain
as a Treatment for Schizophrenia."

One
of the three inventors is Gary Rogers, Ph.D. who is the
Vice President of Pharmaceutical Discovery at Cortex.

AMPALEX(R)(CX516)
is the first compound in the AMPAKINE class to be
administered to humans. The drug is currently the
subject of three Phase I/IIa clinical trials. Anyway,
here's what I, Sir Gary of Halbert, find especially
exciting...